Recipharm
What was big for pharma in 2018?
European Pharmaceutical Manufacturer speaks to some of the leading names in pharmaceutical manufacturing to find out what the key moments have been for them in 2018. Read more
The drug formulation steps to take during first-in-human (FIH) trials
Torkel Gren, Recipharm and Anders Millerhovf, CTC Clinical Trial Consultants discuss the steps needed for drug formulation during first-in-human (FIH) trials, if regulatory approval is to be achieved. Read more
MHRA restricts five products at Recipharm facility
Five non-critical highly potent products supplied by contract development and manufacturing organisation (CDMO) Recipharm have had their manufacturing licence restricted. Read more
The value of serialisation
As we draw ever nearer to the time that compliance with the European Falsified Medicines Directive (FMD) is required, we discuss the value of serialisation beyond compliance and outsourcing with six leading solutions providers. Read more
Recipharm gains EU Hub's approval to submit serialisation data
Contract development and manufacturing organisation (CDMO) Recipharm has received approval by the European Medicines Verification Organisation (EMVO) to submit serialisation data to the European Hub. Read more
Meeting compliance: Challenges for CDMOs before the EU FMD deadline
In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019. Read more
Post-Brexit strategy vote — pharma industry opinions
Last week, the UK government saw heated debates and closely contested votes on the post-Brexit strategy, including a favourable outcome for the future relationship of the UK and the European Medicines Agency (EMA) Read more
Less than six months until EMA relocates: What are some of the thoughts from industry?
Now we have just passed the six-month marker (1 July) until the European Medicines Agency (EMA) moves from its current location in London to Amsterdam, as a result of Brexit, we gauge industry response to this change… Read more
Recipharm acquires Sanofi’s Holmes Chapel manufacturing centre and business
CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market. Read more
Recipharm partners with Hadasit, supporting regional growth
Contract development and manufacturing organisation (CDMO), Recipharm, has partnered with Hadasit Medical Research Services and Development to deliver combined clinical, biological and chemical services. Read more
CMO Leadership Awards recognise Recipharm as winner in six categories
Contract development and manufacturing organisation (CDMO), Recipharm, has been recognised in the CMO Leadership Awards for 2018, organised by Life Science Leader. Read more
Recipharm reveals winner of 2017 International Environmental Award
Contract development and manufacturing organisation (CDMO), Recipharm, has revealed that the winner of its 2017 International Environmental Award is Karen Kidd Read more
Licensing agreement formed for co-development of new value added medicines
Contract development and manufacturing organisation (CDMO), Recipharm, has signed a licensing agreement with Canadian drug development company, Altus Formulation, to offer new drug delivery technologies for value added medicines. Read more
The final countdown is on for EU FMD compliance: What are the experts saying?
Today (Friday 9 Feburary 2018) marks the precise point that we are a year away until the European Union Falsified Medicines Directive (EU FMD) comes into force. Here, we feature some expert opinions Read more
Recipharm acquires remaining shares in Indian company
Recipharm has taken a step further in its development and growth in the Indian market by acquiring the remaining shares in Nitin Lifesciences. Read more
Sector highlights: Recipharm interview
Mark Quick, executive vice president of corporate development, Recipharm, goes into detail about the opportunities his company has faced this year as well as the challenges. Read more
Inflection point: Reviewing the industry opportunities, challenges and trends of 2017
With the industry experiencing dramatic change, from regulatory changes to investments in capacity and the uncertainty of the political landscape, we asked several industry heads to review the opportunities, challenges and trends of 2017. Read more
Recipharm recognised for its commitment to its operations in France
CDMO, Recipharm, has been awarded with ‘le Prix d’Excellence 2017 — Spécial Sciences de la vie’ by the Swedish Chamber of Commerce in France in recognition of its commitment to its French operations Read more
Pharma cannot afford to relax on DSCSA, experts say
Today (Monday 27 November) marks the original deadline date for the DSCSA. While the FDA has delayed its enforcement of compliance with these serialisation requirements by a year, pharma is still required to legally comply. Industry tells us more… Read more
The top five tweets: From Merck to BioLive — what did EPM readers rate this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more
